Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1994-12-08
1997-02-11
Crouch, Deborah
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
424 932, 4353201, 935 57, 935 62, A61K 4800, C12N 1500
Patent
active
056018185
ABSTRACT:
A method is provided for eliminating cancer cells from a population of cells containing cancer cells and noncancerous cells in vitro or in vivo comprising: (a) providing a mixture of noncancerous cells and cancer cells; (b) contacting the cancer cells with transgenic cancer cells comprising a foreign gene such as the herpes virus thymidine kinase gene that renders the transgenic cancer cells susceptible to a therapeutic agent; and (c) contacting the transgenic cancer cells with an amount of said therapeutic agent effective to kill both the transgenic cancer cells and the cancer cells.
REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
Cotter et al., Anticancer Research, 10, 1153 (1990).
Journal of the National Cancer Institute, v82, No. 4, issued 21 Feb. 1990, F. L. Moolten et al., "Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors", pp. 297-300, especially pp. 298-299.
Biochimica et Biophysica Acta, V697, issued 1982, G. Tsushimoto et al., "Recovery from Inhibition of Transcription in Gamma-Irradiated Euglena Cells", pp. 14-19, expecially p. 17.
Cancer Research, v33, issued Feb. 1973, E. C. Holmes et al., "Delayed Cutaneous Hypersensitivity to Cell-free Tumor Antigens", pp. 199-202, entire document.
Wolff et al., Science, 247, 1465 (1990).
Mann et al., Cell, 33, 153 (1983).
Land et al., Science, 222, 771 (1983).
Hanahan, Annu. Rev. Genet., 22, 479 (1988).
Huber, Fed. Amer. Soc. Exper. Biol. J., 3, 5 (1989).
Drebin et al., Cell, 41, 695 (1985).
Moolten, Cancer Res., 46, 5276 (1986).
Moolten, Med. Hypotheses, 24, 43, (1987).
Fialkow, Biochim. Biophys. Acta, 458, 283 (1976).
Nishiyama et al., J. Gen. Virol., 45, 227 (1979).
Eglitis et al., Biochem. Biophys. Res. Commun., 151, 201 (1988).
Eglitis et al., BioTechniques, 6, 608 (1988).
Anderson et al., Cold Spring Harbor Symp. Quant. Biol., 51, 1073 (1986).
Anderson, Science, 226, 401 (1984).
Rosenberg et al., New Engl. J. Med., 316, 889 (1987).
Asher, A. L., et al., "Murine Tumor Cells Transduced with the Gene For Tumor Necrosis Factor-.alpha.--Evidence For Paracrine Immune Effects of Tumor Necrosis Factor Against Tumors," J. Immunol., 146, 3227-3224 (1991).
Fearon, E. R., et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response," Cell, 60, 397-403 (1990).
Moolton, F. L., et al., "Lymphoma Regression Induced by Ganciclovir in Mice Bearing a Herpes Thymidine Kinase Transgene," Human Gene Therapy, 1, 125-134 (1990).
Russell, S. J., et al., "Lymphokine Gene Therapy For Cancer," Immunol. Today, 11, 196-200 (1990).
Tsuhimoto et al (1982) Biochim Biophys Acta 697, 14-19.
Holmes et al (1973) Cancer Res. 33, 199-202.
Moolten et al (1990) J. Natl. Cancer Instit. 82, 297-300.
Abraham George N.
Freeman Scott M.
Koeplin David
McCune Craig S.
Moolten Frederick L.
Crouch Deborah
University of Rochester
LandOfFree
Cancer therapy utilizing malignant cells expressing HSV-TK does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer therapy utilizing malignant cells expressing HSV-TK, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy utilizing malignant cells expressing HSV-TK will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-339713